125 related articles for article (PubMed ID: 38342726)
1. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
Pepeler MS; Tıglıoglu M; Dagdas S; Ozhamamcıoglu E; Han U; Albayrak A; Aydın MS; Korkmaz G; Pamukcuoğlu M; Ceran F; Albayrak M; Ozet G
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e161-e167. PubMed ID: 38342726
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia.
Eliacik E; Isik A; Aydin C; Uner A; Aksu S; Sayinalp N; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Haznedaroglu IC
Hematology; 2015 Aug; 20(7):392-6. PubMed ID: 25517484
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.
Hidalgo-Lόpez JE; Kanagal-Shamanna R; Quesada AE; Gong Z; Wang W; Hu S; Medeiros LJ; Bassett RL; d'Orcy E; Yin CC; Cortes J; Jabbour EJ; Kantarjian HM; Bueso-Ramos CE
Cancer; 2018 Oct; 124(19):3849-3855. PubMed ID: 30321462
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Bueso-Ramos CE; Cortes J; Talpaz M; O'Brien S; Giles F; Rios MB; Medeiros LJ; Kantarjian H
Cancer; 2004 Jul; 101(2):332-6. PubMed ID: 15241831
[TBL] [Abstract][Full Text] [Related]
5. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
Straetmans N; Ma DD; Nevell DF; Arthur C
Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
[TBL] [Abstract][Full Text] [Related]
6. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report.
Lee MH; Song A; Li JY
Diagn Pathol; 2024 Jan; 19(1):21. PubMed ID: 38268039
[TBL] [Abstract][Full Text] [Related]
7. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
[TBL] [Abstract][Full Text] [Related]
8. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Tanrikulu Simsek E; Eskazan AE; Cengiz M; Ar MC; Ekizoglu S; Salihoglu A; Gulturk E; Elverdi T; Ongoren Aydin S; Senem Demiroz A; Buyru AN; Baslar Z; Ozbek U; Ferhanoglu B; Aydin Y; Tuzuner N; Soysal T
J Clin Pathol; 2016 Sep; 69(9):810-6. PubMed ID: 26811428
[TBL] [Abstract][Full Text] [Related]
9. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
10. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
11. Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Ni J; Hong J; Zhang Z; Li Q; Xia R; Zeng Q; Sun G
Leuk Lymphoma; 2020 May; 61(5):1195-1200. PubMed ID: 31858854
[TBL] [Abstract][Full Text] [Related]
12. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
13. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
[TBL] [Abstract][Full Text] [Related]
14. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
17. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Rios MB; Shan J; Cortes J
Leuk Lymphoma; 2005 Jul; 46(7):993-7. PubMed ID: 16019549
[TBL] [Abstract][Full Text] [Related]
18. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis in Patients of Chronic Myeloid Leukemia in Chronic Phase at Presentation.
Hamid A; Ashraf S; Qamar S; Naveed MA; Hameed A; Farooq MA
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1096-1100. PubMed ID: 31659970
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
